Herein, we found that rapamycin treatment promotes TGM2 expression in mTORC1-hyperactive cancer cells, including tsc1-/- and tsc2-/- MEFs, TSC2-deficient patient-derived cells, MCF-7 and 786-O cells. Here, TSC1 is linked to cancer.